The Indian Journal of Pediatrics

, Volume 63, Issue 5, pp 583–589 | Cite as

Dexamethasone in bacterial meningitis: To use or not to use?

  • Aditya Kaul
  • Sulachni Chandwani
Symposium : Controversies in Pediatrics-Part II


Permanent neurologic disabilities are seen in up to a quarter of survivors of bacterial meningitis despite major improvements in therapy. Experimental studies have demonstrated that most of the pathology in meningitis is mediated by inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1), which are produced by host cells in response to bacterial invasion of the meninges. Dexamethasone has been used in a number of clinical trials to moderate the host response and to improve neurologic outcome of meningitis. Results of six randomized, placebo controlled trials are summarized in this review. Dexamethasone treatment did not lower mortality. Only a moderate, but not a significant reduction in the neurologic and audiologic sequelae was seen in dexamethasone recipients whenHaemophilus influenzae type b (Hib) was the causative agent of meningitis. Following routine use of Hib vaccine, meningitis caused by this agent has virtually disappeared in the USA. Hence, findings from these trials may no longer be applicable in countries with high rates of immunization against Hib. Presently, there is little or no evidence showing a benefit of dexamethasone therapy in meningitis caused byS. pneumoniae orN. meningitidis. Global emergence of penicillin and cephalosporin resistantS. pneumoniae has raised new concerns about the use of dexamethasone in pneumococcal meningitis. Since dexamethasone significantly decreases the penetration and concentration of vancomycin and ceftriaxone in the CSF and delays CSF sterilization, adjunctive dexamethasone therapy may increase the risk of treatment failure in meningitis caused by antibiotic resistant pneumococci. An antibiotic combination should be used in the treatment of meningitis caused by antibiotic resistant pneumococci, particularly if dexamethasone is also being administered concurrently.

Key words

Meningitis Dexamethasone Haemophilus influenzae Streptococcus pneumoniae antibiotic resistance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Taylor HG, Michaels RH, Mazur PMet al. Intellectual neuropsychological, and achievement outcomes in children six to eight years after recovery from Haemophilus influenzae meningitis.Pediatrics 1984; 74: 198–205.PubMedGoogle Scholar
  2. 2.
    Quagliarello V, and Scheid WMet al. Bacterial meningitis: pathogenesis, pathophysiology, and progress.N Eng J Med 1992; 327: 864–872.CrossRefGoogle Scholar
  3. 3.
    Kalpan SL, Hawkins EP, Kline MWet al. Invasion of the inner ear by Haemophilus influenzae type b in experimental meningitis. JInfect Dis 1989; 159: 923–930.Google Scholar
  4. 4.
    Mustafa MM, Ramilo O, Mertsola Jet al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type b meningitis.J Infect Dis 1989; 160: 818–825.PubMedGoogle Scholar
  5. 5.
    Prober CG. The role of steroids in the management of children with bacterial meningitis.Pediatrics 1995; 95: 29–31.PubMedGoogle Scholar
  6. 6.
    Lebel MH, Freij BJ, Syrogiannopoulos GAet al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials.N Engl J Med 1988; 319: 964–971.PubMedCrossRefGoogle Scholar
  7. 7.
    Odio CM, Faingezicht I, Paris Met al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis.N Engl J Med 1991;324: 1525–1531.PubMedCrossRefGoogle Scholar
  8. 8.
    Schaad UB, Lips U, Gnehm HEet al. Dexamethasone therapy for bacterial meningitis in children.Lancet 1993; 342: 457–461.PubMedCrossRefGoogle Scholar
  9. 9.
    King SM, Law B, Langley JMel al. Dexamethasone therapy for bacterial meningitis. Better never than late?,Can J Infect Dis 1994; 5: 210–215.Google Scholar
  10. 10.
    Wald ER, Kaplan SL, Mason EOet al. Dexamethasone therapy for children with bacterial meningitis.Pediatrics 1995; 95: 21–28.PubMedGoogle Scholar
  11. 11.
    Schaad UB, Suter 5, Gianella-Borradori Aet al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. NEngl J Med 1990; 322: 141–147.PubMedCrossRefGoogle Scholar
  12. 12.
    Adams WG, Deaver KA, Cochi SLet al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.JAMA 1993; 269: 221–226.PubMedCrossRefGoogle Scholar
  13. 13.
    Girgis NI, Zoheir F, Mikhail IAet al. Dexamethasone treatment for bacterial meningitis in children and adults.Ped Inf Dis J 1989; 8: 848–851.CrossRefGoogle Scholar
  14. 14.
    Kennedy WA, Hoyt MJ, McCracken GH Jr. The role of corticosteroid therapy in childrenwith pneumococcal meningitisAm J Dis Child 1991; 145: 1374–1378.PubMedGoogle Scholar
  15. 15.
    Kanra GY, Ozen H, Secmeer G, Ceyhan M, Ecevit Z, Belgin E. Beneficial effects of dexamethasone in children with pneumocccal meningitis.Ped Inf Dis J 1995; 14: 490–494.CrossRefGoogle Scholar
  16. 16.
    Paris MM, Ramilo O, McCracken GH Jr. Management of meningitis caused by penicillin-resistant streptococcus pneumoniae.Antimicrob Agents Chemother 1995; 39: 2171–2175.PubMedGoogle Scholar
  17. 17.
    Report of the Committee of Infectious Diseases of the American Academy of Pediatrics. 23rd Ed. Dexamethasone therapy for bacterial meningitis in infants and children. Elk Grove Village, II: American Academy of Pediatrics; 1994; 558–559.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 1996

Authors and Affiliations

  • Aditya Kaul
    • 1
  • Sulachni Chandwani
    • 1
  1. 1.Department of Pediatrics, Division of Pediatric Infectious Diseases and ImmunologyNew York University School of MedicineNew YorkUSA

Personalised recommendations